针对免疫检查点分子BTN2A2的抗体增强了抗瘤免疫力
1National Joint Local Engineering Laboratory for Cell Engineering and Biomedicine Technique, 6 Ankang Avenue, Guian New District, Guizhou, China, 561113; Department of Histology and Embryology, Guizhou Medical University, 6 Ankang Avenue, Guian New District, Guizhou, China, 561113; Key Laboratory for Research on Autoimmune Diseases of Higher Education schools in Guizhou Province, 6 Ankang Avenue, Guian New District, Guizhou, China, 561113.
一种针对BTN2A2免疫检查点的新疗法有效地减少了胰腺癌和质瘤模型中的瘤大小. 这种新型免疫检查点抑制剂 (ICI) 增强了抗瘤免疫细胞的活性,并使瘤微环境正常化.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 瘤通过利用免疫检查点来逃避免疫反应.
- 准免疫检查点是癌症免疫疗法的关键策略.
研究的目的:
- 开发和评估一种针对BTN2A2.2.的新型免疫检查点抑制剂 (ICI).
- 在临床前癌症模型中评估抗BTN2A2单克隆抗体 (mAb) 的疗效.
主要方法:
- 开发了一种抗BTN2A2 mAb,以中和BTN2A2的抑制作用.
- 在胰腺癌和质瘤的小鼠模型中服用抗BTN2A2 mAb.
- 分析了瘤缩,CD8+T细胞透,以及瘤微环境中的免疫细胞组成.
主要成果:
- 在胰腺癌 (35.8%) 和质瘤 (51.2%) 模型中,抗BTN2A2治疗显著降低了瘤大小.
- 增加了CD8+瘤透淋巴细胞 (TILs) 的分别是1.7倍和2.2倍.
- 通过增加有益的免疫细胞 (B细胞,M1巨细胞) 和减少抑制细胞 (M2巨细胞,MDSCs,Tregs) 来使瘤微环境正常化.
结论:
- 用mAb准BTN2A2免疫检查点是癌症治疗的一个有希望的策略.
- 这种方法使免疫抑制瘤微环境正常化,并抑制瘤生长.
- 在治疗"冷"瘤方面,BTN2A2抑制可能特别有效.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
